Edition:
United Kingdom

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.63USD
9 Feb 2018
Change (% chg)

-- (--)
Prev Close
$81.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
133,189
52-wk High
$82.74
52-wk Low
$34.98

Chart for

About

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $3,115.66
Shares Outstanding(Mil.): 21.99
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Advanced Accelerator Applications Enters Into Worldwide License Agreement With Cancer Targeted Technology

* ADVANCED ACCELERATOR APPLICATIONS SA - ENTERED INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH CANCER TARGETED TECHNOLOGY

12 Feb 2018

BRIEF-Advanced Accelerator Applications To Withdraw ADSs From Nasdaq Global Select Market​

* ADVANCED ACCELERATOR APPLICATIONS SA - ‍NOTIFIED NASDAQ STOCK MARKET OF ITS DETERMINATION TO WITHDRAW ADSS FROM LISTING ON NASDAQ GLOBAL SELECT MARKET​

22 Jan 2018

BRIEF-Advanced Accelerator Applications Announces Commencement Of Novartis Tender Offer

* ADVANCED ACCELERATOR APPLICATIONS ANNOUNCES COMMENCEMENT OF NOVARTIS TENDER OFFER

07 Dec 2017

BRIEF-Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis

* ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS

05 Dec 2017

BRIEF-Advanced Accelerator Applications reports qtrly loss per share EUR​ ‍0.26

* Advanced Accelerator Applications reports 39% sales growth for third quarter 2017

17 Nov 2017

Novartis picks Centerview to explore sale of dermatology unit: sources

LONDON/FRANKFURT Swiss drugmaker Novartis is working with Centerview to review options for its dermatology business, including a possible sale, as it trims non-core assets, two sources familiar with the matter told Reuters.

02 Nov 2017

Novartis picks Centerview to explore sale of dermatology unit -sources

LONDON/FRANKFURT, Nov 2 Swiss drugmaker Novartis is working with Centerview to review options for its dermatology business, including a possible sale, as it trims non-core assets, two sources familiar with the matter told Reuters.

02 Nov 2017

Novartis to buy French cancer specialist AAA for $3.9 billion

ZURICH Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.

30 Oct 2017

UPDATE 3-Novartis to buy French cancer specialist AAA for $3.9 bln

* French company had first-half sales of $78 mln (Adds Breakingviews link, further detail on Novartis cancer drugs)

30 Oct 2017

Novartis to buy France's Advanced Accelerator for $3.9 billion

ZURICH Swiss drugmaker Novartis on Monday offered to buy France's Advanced Accelerator Applications (AAA) in a $3.9 billion (2.97 billion pounds) cash deal to strengthen the oncology portfolio at the world's biggest maker of prescription medicines.

30 Oct 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.76 -0.70
Pfizer Inc. (PFE.N) $36.01 -0.25
Roche Holding Ltd. (ROG.S) CHF221.70 -2.20
Roche Holding Ltd. (RO.S) CHF225.40 -1.40
Ipsen SA (IPN.PA) €120.00 -0.15
Lexicon Pharmaceuticals, Inc. (LXRX.OQ) $7.96 --
General Electric Company (GE.N) $14.74 -0.31

Earnings vs. Estimates